星奕昂創(chuàng)始人、董事長兼首席執(zhí)行官王立群博士：中國科學(xué)技術(shù)大學(xué)細(xì)胞生物學(xué)學(xué)士、美國馬里蘭大學(xué)巴爾的摩分校分子生物學(xué)博士以及辛辛那提薩維爾大學(xué)工商碩士，美國國立健康研究院(NIH)博士后。
王立群博士在美國和中國的生物制藥領(lǐng)域擁有豐富的專業(yè)技術(shù)和研發(fā)管理經(jīng)驗(yàn)。在成立星奕昂之前，曾任復(fù)星醫(yī)藥副總、首席技術(shù)官和美國凱特合資公司復(fù)星凱特的總裁。用不到三年時間帶領(lǐng)復(fù)星凱特完成了奕凱達(dá)的技術(shù)落地，注冊臨床和生產(chǎn)，成為獲中國藥監(jiān)局批準(zhǔn)上市的首個CAR-T產(chǎn)品。
王立群博士曾在美國寶潔、百時美施貴寶、阿斯利康以及葛蘭素史克中國研發(fā)中心的重要管理崗位上任職近20年，參與和主導(dǎo)了多個新藥的研發(fā)及轉(zhuǎn)化工作。他在西比曼生物科技擔(dān)任首席運(yùn)營官期間，全面管理公司運(yùn)營、細(xì)胞治療產(chǎn)品的生產(chǎn)、藥理和臨床研究，并兼任干細(xì)胞事業(yè)部總經(jīng)理。
Richard Liqun Wang Ph. D., MBA.
? Founder, Chairman and CEO， Neukio Biotherapeutics
? VP & CTO, Fosun Pharma
? Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years
? COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies
? Head of Operations, GSK R&D Center in China
? Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
? Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
? Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.